Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436535 | 0.90 | BRD4 (0.48) | BRD4RAB9ALPAR2CCR1ITGA1 | |
| SCHEMBL5436530 | 0.90 | BRD4 (0.48) | BRD4RAB9ALPAR2CCR1ITGA1 | |
| SCHEMBL4136570 | 0.79 | TRPV4 (0.49) | TRPV4CCR1BMP1MGAM | |
| SCHEMBL17595505 | 0.69 | MAPK1 (0.59) | RAB9ACASP3ALDH1A1KMT2AMAPT | |
| SCHEMBL5447807 | 0.69 | GBA1 (0.59) | BRD4TRPV4CCR1ALDH1A1 | |
| SCHEMBL5447814 | 0.69 | GBA1 (0.59) | BRD4TRPV4CCR1ALDH1A1 | |
| SCHEMBL14360846 | 0.67 | CCR1 (0.52) | TRPV4CCR1ALDH1A1KMT2AMAPT | |
| SCHEMBL5641347 | 0.67 | MAPK1 (0.56) | RAB9ACASP3ALDH1A1KMT2AMAPT | |
| SCHEMBL17275434 | 0.67 | MAPK1 (0.56) | RAB9ACASP3ALDH1A1KMT2AMAPT | |
| SCHEMBL8939993 | 0.66 | ALDH1A1 (0.64) | RAB9ACASP3ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | BRD4 604/4885RAB9A 3595/4885LPAR2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.